Today's Information

Provided by: Tanvex BioPharma, Inc.
SEQ_NO 5 Date of announcement 2022/02/18 Time of announcement 21:54:16
Subject 
 Subsidiary Tanvex BioPharma USA,Inc.
that the company has resolved to conduct
issuance of new shares through cash capital increase
Date of events 2022/02/18 To which item it meets paragraph 11
Statement 
1.Date of the board of directors resolution:2022/02/18
2.Source of capital increase funds:cash capital increase
3.Whether to adopt shelf registration (Yes, please state issuance period/No):
None.
4.Total monetary value of the issuance and number of shares issued (shares
 issued not including those distributed to employees if consisting in
 capital increase from earnings or capital surplus):USD 56,000,000
5.If adopting shelf registration, monetary value and number of shares
to be issued this time:None.
6.The remaining monetary value and shares after this issuance when
adopting shelf registration:None.
7.Par value per share:None.
8.Issue price:None.
9.Number of shares subscribed for by or allocated to employees:None.
10.Number of shares publicly sold:None.
11.Ratio of shares subscribed by or allotted as stock dividends to existing
shareholders:None.
12.Handling method for fractional shares and shares unsubscripted for by
the deadline:None.
13.Rights and obligations of these newly issued shares:Same rights and
obligations as those of the original common shares.
14.Utilization of the funds from the capital increase:
To increase working capital.
15.Any other matters that need to be specified:None.

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Tanvex Biopharma Inc. published this content on 18 February 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 18 February 2022 14:01:05 UTC.